Skip to content Skip to footer
Subscribe Now
Top Performing Drug – Perjeta (January Edition)
INSIGHTS+

Top Performing Drug – Perjeta (January Edition)

Shots:   In continuation of our previous series on the Top-Performing Drug of the month, based on 2021 revenue, this month we have selected Perjeta and prepared a curated analysis report for our readers  Perjeta is indicated for the treatment of HER2-positive metastatic breast cancer, neoadjuvant HER2-positive breast cancer, Adjuvant HER2-positive breast cancer PharmaShots presents a concise…
January 30, 2024

Read more

VIEWPOINTS_Mohamed Eid_2023
VIEWPOINTS

Unlocking Approval: Mohamed Eid Dives into the Exciting Approval of Jardiance for Adult CKD Treatment in a Captivating Chat with PharmaShots

Shots:  Mohamed Eid, VP of Clinical Development & Medical Affairs, Cardio-Renal-Metabolism & Respiratory Medicine, at Boehringer Ingelheim, in a stimulating conversation with PharmaShots sheds light on the recent approval of Jardiance for the treatment of adults with chronic kidney disease   Jardiance’s EMPA Kidney P-III trial results demonstrated a 28% relative risk reduction vs placebo. Jardiance…
December 5, 2023

Read more

VIEWPOINTS_Micah Litow_2023
VIEWPOINTS

Micah Litow shares insights from the 2023 Kalderos Annual Report on drug discount programs

Shots:  Micah Litow, in a stimulating conversation with PharmaShots, shares insights from the 2023 Kalderos Annual Report on drug discount programs   Micah highlights the challenges the drug manufacturers, covered entities, and state payers face on account of US drug discount programs   Micah sheds light on how Kalderos' MDRP Discount Monitoring solution helps drug manufacturers prevent…
November 9, 2023

Read more

New Drug Designations - June 2023
INSIGHTS+

New Drug Designations – June 2023

Shots:  PharmaShots' designation report provides a condensed overview of several drugs and their designations by the US FDA, the EU, China, and the UK. This month’s report includes 7 biological drugs, 13 small molecules and 9 cell and gene therapies  CellCentric’s Inobrodib, for multiple myeloma and Rocket Pharmaceuticals’ RP-A601, for PKP2-arrhythmogenic cardiomyopathy were the two…
July 17, 2023

Read more

VIEWPOINTS_Gina Fusaro_2023
VIEWPOINTS

Gina Fusaro, VP, Development Program Lead at BMS Shares her Views on the Acceptance of sBLA by the US FDA and the EMA Validation on MAA for Opdivo

Shots: Gina gave her views on the acceptance of the sBLA by the US FDA and the validation of the Type II Variation Marketing Authorization Application by the EMA for Opdivo as monotherapy for the treatment of patients with completely resected stage IIB or IIC melanoma She also spoke on the epidemiology of melanoma and…
May 16, 2023

Read more

VIEWPOINTS_Allyson Moellenhoff_2023
VIEWPOINTS

Allyson Moellenhoff, Director of Product Marketing at Kalderos Shares Insights on a New Portal Designed for Drug Manufacturers

Shots: Allyson gave a brief overview of Kalderos and spoke about a new portal designed for drug manufacturers to provide a more efficient way to process drug discount claims She also elaborated on how this Drug Discount Management platform will help drug manufacturers to organize their discounts by taking this data out of Excel spreadsheets…
May 15, 2023

Read more

Load more